Weekly Digest – June 2026 Weekly Digest – June 2026 04 June 2026: Innovent Biologics’ IBI343 met primary endpoint in phase 3 Gastric cancer trial with NDA accepted by NMPA Innovent Biologics has announced that IBI343, a CLDN18.2-targeted antibody-drug conjugate, […]
Weekly Digest – June 2026 Weekly Digest – June 2026 03 June 2026: SOTIO receives U.S. FDA Orphan Drug Designation for SOT106, a potential best-in-class ADC for Sarcoma SOTIO announced that the U.S. FDA has granted Orphan Drug Designation to […]
Weekly Digest – June 2026 Weekly Digest – June 2026 30 May 2026: MediLink Therapeutics announces B7-H3 ADC YL201 met primary endpoint in phase 3 Nasopharyngeal carcinoma study MediLink Therapeutics has announced that its B7-H3-targeted ADC YL201, successfully met the […]
Weekly Digest – June 2026 Weekly Digest – June 2026 04 June 2026: Stipple Bio enters multi-target license agreement with Lonza to advance precision oncology ADC therapies Stipple Bio has strengthened its position in the next wave of ADC innovation […]
Weekly Digest – June 2026 Weekly Digest – June 2026 01 June 2026: Mabion and KriSan Biotech sign letter of intent to explore ADC collaboration supporting strategic ambitions advanced Solid tumor study Mabion and KriSan Biotech have signed a Letter […]
Weekly Digest – June 2026 Weekly Digest – June 2026 29 May 2026: Ratio Therapeutics and PharmaLogic expand manufacturing collaboration to support clinical development of [Ac-225]RTX-2358 Ratio Therapeutics and PharmaLogic have expanded their manufacturing collaboration to support the clinical development […]
